Follica Inc. is a biotechnology firm focused on developing therapies for disorders and conditions of the hair follicle. According to a filing with the U.S. Securities and Exchange Commission, Follica recently raised an additional $7.5 million in equity financing, as part of the firm’s Series B round of funding. This funding came from the company’s previous financial backers, including PureTech, InterWest Partners and Polaris Venture Partners. The total series B capital raised is around $13 million.
Follica specialises in treating hair follicle disorders, including androgenetic alopecia, or male pattern baldness. It is yet unclear how much progress the company has made in developing a new therapy for combating hair loss, or whether this is even their primary objective at this time. Regardless, many individuals are hoping that this additional funding will prompt the release of some new, and highly anticipated, hair loss treatments.